Tividenofusp alfa
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Tividenofusp alfa, covering 2025-08-05 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 [Phase 2, Phase 3]